Aandeel CRNO B CERENO SCIENTIFIC AB (PUBL)
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen Cereno Scientific AB (publ) NORDIC GROWTH MARKET

Aandelen

CRNO B

SE0008241558

slotkoers NORDIC GROWTH MARKET
Andere beurzen
 00:00:00 20-06-2023 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
0,521 SEK -7,13% Intraday-grafiek van Cereno Scientific AB (publ) +7,98% -76,90%
16/04 Cereno Scientific AB (Publ) keurt verkiezing van nieuwe bestuurders goed CI
11/04 Cereno Scientific verkrijgt patentuitbreiding in Canada voor kandidaat-geneesmiddel voor hypertensie MT

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
Report from Annual General Meeting 2024 of Cereno Scientific AB
Cereno Scientific AB Approves Election of New Directors
Cereno Scientific Secures Patent Expansion in Canada for Hypertension Drug Candidate
Cereno Scientific expands patent protection for epigenetic HDAC inhibitor CS1:s second patent family
Cereno Scientific Files Clinical Trial Application for Blood Cut Treatment
Cereno Scientific submits Clinical Trial Application (CTA) for first-in-human Phase I study with novel epigenetic HDACi drug candidate CS014
Cereno Scientific AB Submits Clinical Trial Application for First-In-Human Phase I Study with Novel Epigenetic HDACi Drug Candidate CS014
Cereno Scientific Receives Patent Expansion in Europe
Cereno Scientific announces extended patent protection in Europe for CS585 program
Cereno Scientific releases Insights Video Season 3 Episode 9 with Dr. Björn Dahlöf, CSO, Cereno Scientific
Cereno Scientific participates at the ISHLT 44th Annual meeting and Scientific sessions to expand network and meet with investigators for the Phase II Study in PAH
Cereno Scientific releases Insights Video Season 3 Episode 8 with Björn Dahlöf, CSO, Cereno Scientific
Cereno Scientific publishes Annual Report for 2023
Cereno Scientific participates at the upcoming medical conference ACC.24 to further build presence in the Cardiology community
Cereno Scientific Obtains New European Patent for Hypertension Drug Candidate
Cereno Scientific announces new patent issued in 25 European countries for Phase II drug candidate CS1
Cereno Scientific announces that a study protocol synopsis for the FDA approved Expanded Access Program for CS1 in PAH has been published on ClinicalTrials.gov
Cereno Scientific Announces A Study Protocol Presented for the FDA Approved Expanded Access Program for CS1 in PAH
Warrants of series TO3 were exercised to approximately 99.6 percent and Cereno Scientific receives approximately SEK 76.7 million
Cereno Scientific announces new patent issued in Mexico for Phase II drug candidate CS1
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers CRNO B
  4. Koers CRNO B
  5. Nieuws Cereno Scientific AB (publ)
  6. Andere talen